Publications by authors named "Ramon Tiu"

Claim this Profile
C
Clinicogenomic factors and treatment patterns among patients with advanced non-small cell lung cancer with or without brain metastases in the United States.
Emily Nash Smyth, Jincy John, Ramon V Tiu, Melinda Dale Willard, Julie Kay Beyrer

Oncologist· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.
Alexander E Perl, Richard A Larson, Nikolai A Podoltsev, Stephen Strickland, Eunice S Wang, Ramon Tiu

Transplant Cell Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax Plus Gilteritinib for -Mutated Relapsed/Refractory Acute Myeloid Leukemia.
Naval Daver, Alexander E Perl, Joseph Maly, Mark Levis, Ellen Ritchie, Ramon V Tiu

J Clin Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
Eunice S Wang, Pau Montesinos, Mark D Minden, Je-Hwan Lee, Michael Heuser, Ramon V Tiu

Blood· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
Alexander E Perl, Richard A Larson, Nikolai A Podoltsev, Stephen Strickland, Eunice S Wang, Ramon Tiu

Blood· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
Alexander E Perl, Naoko Hosono, Pau Montesinos, Nikolai Podoltsev, Giovanni Martinelli, Ramon V Tiu

Blood Cancer J· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ERK Inhibitor LY3214996-Based Treatment Strategies for -Driven Lung Cancer.
Jens Köhler, Yutong Zhao, Jiaqi Li, Prafulla C Gokhale, Hong L Tiv, Ramon V Tiu

Mol Cancer Ther· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Characteristics, Treatments, and Concurrent Mutations in Non-Small Cell Lung Cancer Patients With NF1 Mutations.
Lee Bowman, Ramon Tiu, Emily Nash Smyth, Melinda Dale Willard, Li Li

Clin Lung Cancer· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.
Ellen Weisberg, Chengcheng Meng, Abigail Case, Martin Sattler, Hong L Tiv, Ramon V Tiu

Leukemia· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers.
Irem Ozkan-Dagliyan, J Nathaniel Diehl, Samuel D George, Antje Schaefer, Bjoern Papke, Ramon V Tiu

Cell Rep· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.
Ellen Weisberg, Chengcheng Meng, Abigail Case, Martin Sattler, Hong L Tiv, Ramon V Tiu

Leukemia· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer.
Ryan J Sullivan, Antoine Hollebecque, Keith T Flaherty, Geoffrey I Shapiro, Jordi Rodon Ahnert, Ramon V Tiu

Mol Cancer Ther· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine.
Shripad V Bhagwat, William T McMillen, Shufen Cai, Baohui Zhao, Matthew Whitesell, Ramon V Tiu

Mol Cancer Ther· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma.
Johanna Bendell, Valerie Andre, Alan Ho, Ragini Kudchadkar, Michael Migden, Ramon V Tiu

Clin Cancer Res· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway.
Lakshmi Reddy Palam, Raghuveer Singh Mali, Baskar Ramdas, Sridhar Nonavinkere Srivatsan, Valeria Visconte, Ramon V Tiu

JCI Insight· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with or Mutations.
Yung-Mae M Yao, Gregory P Donoho, Philip W Iversen, Youyan Zhang, Robert D Van Horn, Ramon V Tiu

Clin Cancer Res· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, Jean-Jacques Kiladjian, Ramon V Tiu

Lancet Haematol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia.
Saroj Vadhan-Raj, Rafat Abonour, Jonathan W Goldman, David A Smith, Christopher A Slapak, Ramon V Tiu

J Hematol Oncol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular and phenotypic heterogeneity of refractory anemia with ring sideroblasts associated with marked thrombocytosis.
Valeria Visconte, Ali Tabarroki, Edy Hasrouni, Jaroslaw P Maciejewski, Eric D Hsi, Ramon V Tiu

Leuk Lymphoma· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safe and effective use of ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation.
William Shomali, Cheryl Redmond, Samjhana Bogati, Cassandra Zimmerman, Valeria Visconte, Ramon V Tiu

Leuk Lymphoma· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations.
Betty Ky Hamilton, Valeria Visconte, Xuefei Jia, Ali Tabarroki, Hideki Makishima, Ramon V Tiu

Am J Hematol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.
Tariq I Mughal, Nicholas C P Cross, Eric Padron, Ramon V Tiu, Michael Savona

Haematologica· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes.
Jing Ai, Valeria Visconte, Ali Tabarroki, Edy Hasrouni, Betty K Hamilton, Ramon V Tiu

Clin Lymphoma Myeloma Leuk· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.
Michael R Savona, Luca Malcovati, Rami Komrokji, Ramon V Tiu, Tariq I Mughal

Blood· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current and novel therapeutic approaches in myelodysplastic syndromes.
Fayez Estephan, Ramon V Tiu

J Community Support Oncol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis